Developing a new generation of vaccines and immunotherapeutic drugs Virometix is a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases

102 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Accelerating drug discovery to transform patients' lives Effective 11/22/21, Acceleron Pharma Inc. is now a wholly-owned subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada) http://merck.com Biopharmaceuticals, Orphan Disease Therapeutics, Rare Diseases, and Serious Diseases

673 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Revolutionizing cell therapy for inflammatory diseases via neonatal cardiac progenitor cells and their secretomes Revolutionizing cell therapy to address inflammatory diseases driven via neonatal cardiac progenitor cells and their secretomes.

286 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. AlmeeTM (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. …

20 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Belgium biotech company providing unique pipeline of medical devices in OsteoArthritis, skin aging and ophthalmology. Capitalizing on a history of innovation and expertise in exclusive natural chitosan chemistry, KiOmed Pharma, a spinout from KitoZyme, develops a unique pipeline of medical devices that address unmet medical needs in high impact pathologies and major social burdens such as invalidating OsteoArthritis, skin aging and ophthalmology. Medical Devices & Implants, Biomaterials, Rheumatology & Joint Health, Dermatology, Biosurgery, Regenerative Medicine, Ultrapure Chitosan, and Animal-free Chitosan

90 similar entities Type: Startup Activities: deeptech healthtech Technologies: Synthetic Biology

Life-Transforming Medicines for Patients Living with Serious Rare Diseases VectivBio AG is a clinical-stage biotechnology company focused on rare diseases with a well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. The company is led by a world-class leadership team with deep expertise in rare diseases and a track record of success in R&D, commercialization and …

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing best-in-class NNMT inhibitors with a dual therapeutic effect to benefit patients with metabolic syndrome Cantoni Therapeutics is a biopharmaceutical spinout company from the University of Leiden (NL) developing best-in-class inhibitors of a single enzyme with a dual therapeutic effect to benefit patients with metabolic syndrome.

99 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Our rational design approach in therapeutics offers a paradigm shift in disease, making the untreatable, treatable. We're pioneering a new era in drug design and development with rationally designed medicines leveraging human capabilities in advanced chemistry and biotech advancements. Our approach centers around biomimicy selectively targeting central cascades that drive disease. Our lead program is in development in kidney disease and has the potential to modify disease outcomes for millions of patients.

68 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Affirma Biotech develops new products to overcome the challenge of Multi Drug Resistant and Chronic Infections Affirma Biotech is a start-up company specialized in the discovery and development of new anti-infective drugs via immunomodulation.

479 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Small molecule therapeutics for weight loss with preservation of muscle function and lean mass in obesity. MitoRx Therapeutics is a preclinical stage platform biotech developing a new category of innovative small molecule mitochondrial metabolic modulators for weight loss with muscle protection in obesity-related indications and metabolic disease. mitochondrial disease, neuromuscular disease, biotech, preclinical, drug discovery, mitochondria, MitoRx, muscular dystrophy, neurodegenerative disease, first-in-class, obesity, diabetes, muscle preservation, cardiometabolic, muscle protection, and weight loss

34 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Glox Therapeutics Ltd. is developing novel precision antibiotics based on protein bacteriocins, which have potent narrow-spectrum activity to target Gram-negative Antimicrobial Resistant (AMR) pathogens.

75 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Transforming cancer and autoimmune treatments with unique IL-1RAP targeting approaches Advesya is a pioneering and transformative biotechnology company developing therapies for difficult-to-treat cancers. Haematology & Oncology, Antibody Drug Conjugate, Cell Therapy, and Autoimmune

430 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Dedicated to developing treatments for rare diseases originated from nonsense mutations Genvade aims to harness the power of nonsense mutation readthrough molecules to develop treatments for some of the most burdensome rare diseases. Our lead compound targets indications include cystic fibrosis, Duchenne muscular dystrophy and other genetic diseases. small molecules, drug discovery and development, rare diseases, nonsense mutation corrector, cystic fibrosis, genetic diseases, oncology, readthrough, and Duchenne

95 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Antineo aims to accompany customers in the preclinical development of novel anticancer agents. We provide services and strategic advice for preclinical development, optimal choice of in vitro and in vivo models as well as strategic input on potential indications to target in the therapeutic landscape. Développement préclinique, in vitro, ex vivo, in vivo, Preuve de concept, Expertise scientifique en pharmacologie, and Modèles à façon

147 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

French biotech company targeting the Adipocyte to treat insulin resistance, type 2 diabetes and associated comorbidities AdipoPharma is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis. Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

59 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Entreprise de dispositif médical de diagnostic in vitro : Noratest® In vitro diagnostic medical device Diagnostic, Innovation, Maladies neurodégénératives, Alzheimer, Neurosciences, Entreprise, and Entrepreneuriat

Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Rewriting the rules of drug creation Cellarity is fundamentally redesigning the way drugs are created. By shifting the focus from a single target to the underlying cellular dysfunction, the company unravels the complexity of disease biology to create medicines that are out of reach with the target-based drug discovery approach. Founded by Flagship Pioneering in 2017, Cellarity has developed a platform that utilizes proprietary AI models trained on over 30 million single cell transcriptomes to uncover novel actionable biology and create non-intuitive drug candidates in a vast array of diseases. The company currently has programs ongoing in several disease areas …

290 similar entities Type: Startup Activities: biotech deeptech Technologies: A.I. Synthetic Biology

Cell Signaling Technology for Organ Repair and Regeneration Cell Signaling Technology for Organ Repair and Regeneration We care for liver Our advanced therapy aims to restore liver function thanks to immunomodulatory and regenerative properties of Hepastem Cell therapy, Acquired liver diseases, Liver diseases, liver based genetic diseases, NASH, ACLF, Antibodies, Clinical stage, Chronic liver disease, Fatty liver, Acute liver disease, Regenerative medicine, Biotech, and Biotechnology

159 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

The KELTICPharma team combine academic innovation, deep target knowledge and corporate drug discovery expertise. In 2019 Prof Andrew Tobin published validation of PfCLK3 as a target with breakthrough potential in the treatment of malaria. Successful drug development would provide a single medicine that is curative, transmission blocking and prophylactic.

102 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Your partner in uro-genital pre-clinical research UROSPHERE is a leading Contract Research Organization specializing in preclinical urogenital, gastro-intestinal and oncological pharmacology studies. We provide the pharmaceutical and biopharmaceutical industries with a unique experimental research platform combining both in vivo models and in vitro assays on human and animal tissues. Innovation, Uro-genital pathologies, Oncology, PDX models, Organoids, CRO, Preclinical Research, Pharmacology, Drug development, Gastrointestinal pathologies, Experimental models, Pain, and Inflammation

121 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Selvita is one of the largest preclinical contract research organizations in Europe, driven by a clear mission: to offer a comprehensive scope of services bridging the gap between early drug discovery and the clinical stage of drug development. biotechnology, pharmaceuticals, drug discovery, preclinical research, bioanalytical development services, bioinformatics, systems biology, proteins, genomics, proteomics, autoimmune disorders, regulatory studies, medicinal chemistry, agrochemical, industrial chemistry, and assay development&screening

544 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

#BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine New ideas, new innovations, new ways of thinking for the medical device industry. We are a pharmaceutical company specialized in the discovery, clinical development, production and commercialization of innovative products in the field of regenerative medicine. At Bioxis Pharmaceuticals, we contribute to transform science into groundbreaking medical device that meet doctors need to improve the health and well-being of their patients in the field of dermatology and aesthetic medicine. Medical Device, Dermatology, Aesthetic, Cosmetic surgery, Regenerative medicine, Ultra-pure chitosan, and Hyaluronic Acid

322 similar entities Type: Startup Activities: healthtech manufacturing deeptech biotech Technologies: Synthetic Biology

Platelet Secretome : a New Therapeutic Strategy Against Neurodegeneration InVenis Biotherapies is a biotech compagny, spin-off from academic laboratory U1172 and Taipei Medical University, developping innovative regenerative therapies based on blood platelet. Thanks to the high therapeutic potential of our product, we target the most severe diseases involving cell death, as the amyotrophic lateral sclerosis.

108 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

We’re using ground-breaking cell technologies to revolutionise global food production - starting with pork Uncommon Bio began with cell-based meat and pioneered RNA delivery innovations, which evolved into their most recent spin out which is focusing on changing medicine through multi-targeting. Their polysaccharide-based delivery platform enables multi-pathway cell programming, offering a safe, efficient and scalable alternative to multi-target therapies. The company is initially targeting severe lung diseases like idiopathic pulmonary fibrosis and is backed by industry leaders from BioNTech and top investors, including Sam Altman, Balderton, Lowercarbon, and Redalpine. science+art, biotech, mRNA, IPF, Pulmonary fibrosis, and delivery

85 similar entities Type: Startup Activities: biotech deeptech foodtech Technologies: Synthetic Biology

Innovation for your health and well-being. Pharmaceutical company, R&D oriented dedicated to the development and marketing of senolytic compounds, food supplements and drugs against aging, age-related degenerative diseases and cancer.

140 similar entities Type: SMB Activities: deeptech biotech healthtech Technologies: Synthetic Biology

Peptide-based therapeutics for treating peripheral pain conditions At Akasi Pharma, we are developing novel peptide-based therapeutics to treat peripheral pain conditions Peptide therapeutics and Peripheral Neuropathic Pain

155 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Targeting CCN signaling to treat fibrosis Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases.

184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing a new class of ADCs based on NMT inhibition to treat cancer We are a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

260 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Unlocking the therapeutic potential of protein stabilisation Outrun Therapeutics is unlocking the therapeutic potential of protein stabilisation by E3 Ligase inhibition for the treatment of cancer and other diseases.

184 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our lead programme is in the area of rare genetic kidney disease.

78 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Making Regenerative Medicine Accessible Roumai Medical is developing next-generation biotechnologies in regenerative medicine and human-machine interface to meet the unmet clinical needs of millions of patients worldwide.

449 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Aiming to provide improved treatments for chronic respiratory diseases through new, innovative drug substances -

421 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Nano Drug Solutions Revolutionizing neuropathy treatment Development of innovative nanomedicines targeting neuropathies, with a particular focus on hereditary neuropathies such as Charcot-Marie-Tooth disease Biothechnology

109 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Peptide Chemistry company for design, synthesis, stability studies and chemical optimisation (SAR studies)- CIR agrement PEPTIDES, PEPTIDE LIBRARIES AND PROTEINS Innovative chemistry for therapeutic, diagnostic and cosmetic applications GENEPEP is a CRO company (with CIR agreement) focused on peptide synthesis & services : - Tools for nanoparticles & surface functionalization - Custom synthesis of peptides, proteins & peptide libraries - Catalog of toxins, peptides & pseudopeptides - Design & synthesis for SAR studies (optimisation of solubility, stability, efficacy,...) - Stability & solubility tests - Partner of European programs, ANR, FUI etc...

419 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Pioneering Therapies for Neuropathic Corneal Pain and Inflammation. NASDAQ: OKYO OKYO Pharma is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP), a severe ocular condition without an FDA approved therapy, and for inflammatory eye diseases.

45 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Regenerative Medicine - Growth Disregulation - Oncology REGULAXIS is a French innovative biotechnology company based at BIOCITECH the technology park of life science of Paris North area. The company is engaged in the research, development and licensing of innovative synthetic molecules for use in human therapies. Its mission is to grant licenses of innovative molecules in a pharmaceutical company after the establishment of a phase II clinical record. REGULAXIS leads its R&D on its own premises, particularly in regard to biochemical and biological experiments, and keeps the mastery of the chemical synthesis of its therapeutic molecules. The company develops its …

257 similar entities Type: Startup Activities: biotech healthtech Technologies: Synthetic Biology

Automated 3D organoid screening technology We integrate standard assays on chip (eg. CRISPR, T-cell, cytotoxicity) to accelerate drug discovery from target to validation, and advance preclinical predictivity

363 similar entities Type: Startup Activities: biotech deeptech healthtech Technologies: Synthetic Biology

Ion channel and GPCR drug discovery using innovative KnotBody technology Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

208 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Pharmaceutical drug development company, focusing on late-stage development for treatment of serious rare diseases. Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

55 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Building on innovative science to create treatments for patients in need ResoTher Pharma ApS is a biotechnology company focused on developing novel and effective peptide therapeutics for cardiovascular disease by targeting inflammation. Biotechnology, Drug Development, and Pharmaceutical Industry

728 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Ilya Pharma 🇸🇪🇺🇸 is bringing local-acting immunotherapies to patients Delivering local-acting immunotherapies to patients ATMP, Gene Therapy, Drug development, Clinical trials, GMP, IBD, Wound treatment, Scar, Topical, Oral, Research, Science, Immunology, Immunophysiology, microbiology, Applied microbiology, Regulatory excellence, Skin, Diabetes, IBD, Cysticfibrosis, SAVI, colitis, Cystic fibrosis, and Inhalation

105 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

To make disease-modifying treatments available to patients with serious or life-threatening conditions Medibiofarma S.L is a clinical-stage biotechnology company founded in 2016 by a group of professionals with extensive experience in Drug Discovery in the pharmaceutical industry. We aim to generate innovative and high quality research programs based on the modulation of clinically validated therapeutic targets for the treatment of cancer and non-cancer diseases. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, IP generation, IBD (Colitis, Crohn), Oncology, CNS, and Synaptopathies

241 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Innovating to Disrupt Cancer Treatment Genoscience Pharma is a French biotech company developing unique small molecules in Oncology. This is the first clinical stage company ever with unique lysosomotropic agents assessed in global clinical trials. For more information, please visit our website, or call us +33 4 91 26 99 50. Liver, Oncology, Clinical Development, Preclinical Development, Discovery, Research & Development, Intellectual Property, Drug Development, and Small Molecule

213 similar entities Type: SMB Activities: biotech deeptech manufacturing Technologies: Synthetic Biology

Innovation in medical needs. Inmedical Therapeutics es un fabricante de productos médicos y soluciones en formato hidrogel ubicado en Vitoria. Biotecnología, Endoscopia, Farmacéutica, and Producto Médico

125 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Breaking Biology Free Our patent-pending biotech platform, Phactory, makes designing synthetic proteins 10,000x more effiicent and reduces the material costs by 100x. We are leveraging Phactory to develop the newest classes of protein-based drugs, including binders (nanobodies, bispecific antibodies), toxic proteins, and phage proteins.

81 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD) Biopharma, Oncology, Precision Medicine, Small Molecules, Targeted Therapy, Biotech, Cancer Therapy, Transcription Factors, Autoimmune Disorders, and Inflammatory Disorders

158 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Novel small-molecule drugs in immunology, fibrosis and women health Clinical-stage biotech company founded by serial entrepreneurs and owned by private & institutional investors. Discovery and development of new chemical entities with strong IP and worldwide rights targeting indications with high unmet medical need in immunology, fibrosis and women health. Medicinal Chemistry, in vitro Pharmacology, Drug Discovery and Development, Inflammation and autoimmune diseases, IP generation, IBD, Ulcerative Colitis, Crohn's disease, Fibrosis, and Uterine fibroids

263 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Advancing precision oncology therapeutics designed to deploy multi-faceted inhibition to reverse cancer resistance AUM Biosciences is focused on advancing a clinical pipeline of precision oncology therapeutics designed to deploy multi-faceted inhibition strategies to reverse cancer resistance biotech, oncology, drug development, Asian-biotech, Precision medicine, Digitalhealth, cancer, and small molecules

602 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

We are Purespring. We are on a mission to radically transform the treatment of kidney diseases. Purespring, which launched in November 2020 with £45 million of funding from Syncona Ltd, is the first company to be directly targeting the podocyte, a specialized kidney cell implicated in many kidney diseases, through AAV gene therapy. This approach is based on the work of Professor Moin Saleem, Professor of Paediatric Renal Medicine at the University of Bristol, where he heads a world leading group researching glomerular diseases. biotechnology, gene therapy, and kidney diseases

33 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Developing novel medications for patients with atrial fibrillation InCarda Therapeutics is a clinical stage drug delivery company developinng novel drugs designed for rapid, safe, and effective cardioversion of atrial fibrillation (AF). AF afflicts over 10 million patients in the US alone and is growing rapidly. Cardiovascular, Biotechnology, Pharmaceuticals, Clinical Development, Drug Formulation, Clinical Research, and Pre-Clinical Research

69 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Advancing iPSC-derived cell therapies to transform care in autoimmune disease and cancer​ Century Therapeutics is an innovative biotechnology company that is building an industry-leading, allogeneic, iPSC-derived cell therapy platform that integrates cutting-edge gene editing, protein engineering, technical development and manufacturing capabilities to generate allogeneic, iPSC-derived therapies for autoimmune diseases and cancer.​ Please note: Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites) or require potential candidates to make purchases of goods or services.​

80 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Interventions for Human Diseases Venture-funded company, discovering and developing oral novel small molecule first-in-class inhibitors of Bach1 (a transcription factor) as transformative potential therapy, globally accessible for patients with sickle cell disease (SCD), renal, cardiometabolic and neurodegenerative and other diseases. Sickle Cell Disease, fetal hemoglobin induction, beta-thalassemia, Renal diseases, cardiometabolic diseases, and neurodegenerative diseases

127 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology

Predicting life-changing drugs for patients with cancer Calico Biosystems is on a mission to help pharma companies create effective, affordable drugs faster to counter cancer multi-omics assay, computational modeling, drug efficacy prediction, combination therapy, and Cell and virus-based therapeutics' efficacy

573 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Exploiting a proprietary tech platform to develop biomolecular tools for therapeutic & synthetic biology applications PartitionBio Exploiting a novel proprietary technology platform to develop biomolecular tools for the use in therapeutic and synthetic biology applications.

168 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Creating Tomorrow's Immunotherapies NXI therapeutics focuses on the research and development of a new generation of selective immunosuppressive drugs for autoimmune diseases and transplantations - with objectives of high efficacy, good safety without adverse effects as seen with conventional immunosuppressants.

212 similar entities Type: Startup Activities: deeptech biotech Technologies: Synthetic Biology

Developing next-generation lipid nanoparticle delivery systems to unlock the potential of RNA therapeutics Axelyf was founded in Iceland in 2022 with the goal of harnessing health benefits of natural molecules through chemistry and delivery engineering.

75 similar entities Type: Startup Activities: healthtech deeptech Technologies: Synthetic Biology

Global Leaders in Mammalian Cell Line Development KBI Biopharma and Selexis SA are consolidating operations as one organization under the KBI Biopharma name. This streamlined approach supports customers in accelerating drug development and manufacturing, creating greater flexibility, efficiencies, and a simplified partner experience. You can follow us on the KBI Biopharma page to stay up-to-date on the latest news, events, and happenings. Cell Line Development, HTS, Cell Line Engineering, Contract Biological Services, Stable Cell Line Development, Cell Engineering, Variant Screening, Research Cell Banks, Monoclonal Antibodies, Whole Genome Sequencing, Bispecific Antibodies, CDMO, Monoclonality Assessment, Biotechnology, Biosimilars, Cell line engineering, Genetic engineering, …

136 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Advancing healthcare through innovative adenosine receptor-based drugs Palobiofarma S.L. is a Spanish biopharmaceutical company dedicated to discovering and developing innovative drugs based on the modulation of adenosine receptors.

254 similar entities Type: SMB Activities: deeptech biotech Technologies: Synthetic Biology

Targeting diseases at their molecular roots Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.

55 similar entities Type: SMB Activities: biotech deeptech Technologies: Synthetic Biology

Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases.

144 similar entities Type: Startup Activities: biotech deeptech Technologies: Synthetic Biology